Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).
1 finding from 1 review
- Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes onlyPeto OR 1.32 [0.61, 2.86]Studies not reportedLow